by Jeffrey Clark on January 27, 2012
 The premier medical device and technology event of the year, AdvaMed 2012: The MedTech Conference has officially launched its new website and opened the call for program panel proposals.
Annually one of the strongest events of the year, Advamed 2012 will be held at the Boston Convention & Exhibition Center on October 1-3. More than 1,900 medical device and diagnostics professionals (including 420 CEOs, presidents and C-level executives) from over 925 companies and organizations and representing 22 countries and 38 U.S. states attended AdvaMed 2011.
AdvaMed 2012 encourages organizers to submit panels that are novel, timely, relevant and valuable in educational content, impart helpful lessons learned, or share proven best practices and have a global appeal.
In additional to the panel proposal opportunity, AdvaMed 2012 sponsorship, exhibitor and company presentations opportunities are also available. To learn more about AdvaMed 2012: The MedTech Conference, visit www.AdvaMed2012.com or call 202-434-7213.
by Jeffrey Clark on January 25, 2012
 With a poison pill provision and staggered Board elections, Illumina seems to be well-protected from unruly suitors during a time when its stock price is so undervalued. So, how will Roche win the chess match with Illumina’s Board and its shareholders?
From the NY Times Blog, a fascinating and well researched portrayal of why there is an obvious chink in the armor at Illumina and how Roche will ultimately win out. As detailed in our last post, Roche is a veteran at these moves, having won longstanding struggles with Ventana & Genentech.
Want to know why? Here are the details regarding corporate structure that will lead Roche to prevail.
NY Times Blog
January 25, 2012
Dr. David Agus, the former oncologist for the late Steve Jobs, is all over the news, following the release of his book “The End of Illness” last month According to Agus, we can do better analyzing the human body and using more advanced technologies to diagnose and prevent disease. After spendings years conducting research and [...]
Read the full article →
January 25, 2012
Roche has its sights set on Illumina, the San Diego based sequencing company. Roche CEO Severin Schwan has repeatedly emphasized the the need for new and better targeted drugs. Illumina would complement Roche beautifully – both with Genentech’s focus on targeted cancer therapies and Roche Diagnostics increasing work in companion diagnostics. Remember that Roche already [...]
Read the full article →
January 24, 2012
Just days ago, President Obama authored an article in the Wall Street Journal entitled, Toward a 21st-Century Regulatory System. While not wholly specific to the life sciences industry, he does address government regulatory process in general as inefficient and makes several inferences to the FDA. As relates to medical devices and the much wrangled 510(k) [...]
Read the full article →
January 24, 2012
Chris Viehbacher has become an outspoken voice since taking the helm at chairman of the board for PhRMA. His latest comments are aimed at the FDA, claiming that the pharmaceutical industry may stop investing in medicines to treat diseases like diabetes or obesity without more explicit guidelines from Rockville. What Viehbacher sees happening is companies [...]
Read the full article →
January 21, 2012
Hank Kucheman, Boston Scientific Interim CEO, and Michael Mahoney, Boston Scientific Icoming CEO, shed insight on a pro-longed CEO transition and pricing pressures in the device industry. Remember that Mahoney was the Group Chairman of J&J’s Medical Device and Diagnostics business until Boston Scientific recruited him away earlier this year. BSCI and J&J wrangled over [...]
Read the full article →
January 20, 2012
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates. These are nervous times at Alkermes and Amylin. Bydureon is a long-acting form of the drug exenatide (Byetta) and was developed through a partnership between Amylin and [...]
Read the full article →
January 19, 2012
A final agreement between the FDA and the pharmaceutical industry on user fees for prescription, generic and biosimilar drugs was submitted for approval by Congress. “At a time of greater budgetary constraint, user fees provide a critical way for leveraging appropriated dollars, ensuring that the FDA has the resources needed to conduct reviews in a [...]
Read the full article →
January 18, 2012
The medical device market in China will rise 17% to $5 billion this year, according to a report from Citigroup. China’s growth is no secret, yet medical device spending will be boosted by growing demand from hospitals as they modernize and improve their infrastructure. The Citigroup report includes Medtronic, GE Healthcare, Stryker and Johnson & [...]
Read the full article →
|
